| scholarly article | Q13442814 |
| P50 | author | Raj K S Badhan | Q56422380 |
| P2093 | author name string | Swapnil Khadke | |
| Yvonne Perrie | |||
| P2860 | cites work | Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response | Q57955486 |
| Dynamics of lymph and plasma protein exchange | Q73051461 | ||
| Passage of molecules through capillary wals | Q73270509 | ||
| Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice | Q80629501 | ||
| Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses | Q82234204 | ||
| A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines | Q39373123 | ||
| The investigation of capillary permeability in single vessels | Q39804900 | ||
| Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys | Q40545249 | ||
| Physiological parameter values for physiologically based pharmacokinetic models | Q41556435 | ||
| Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model | Q41559765 | ||
| Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen | Q43252469 | ||
| Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human | Q44019028 | ||
| Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers | Q45233558 | ||
| Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines | Q46986963 | ||
| Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response | Q47297457 | ||
| The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. | Q47373276 | ||
| Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions | Q48567088 | ||
| Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. | Q51975107 | ||
| Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. | Q52379785 | ||
| Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses. | Q54675280 | ||
| Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. | Q30930928 | ||
| The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes | Q33273936 | ||
| Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements | Q33367582 | ||
| Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability | Q34083937 | ||
| Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model | Q34099756 | ||
| Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses | Q34217826 | ||
| Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial | Q34663035 | ||
| Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation | Q34920323 | ||
| The flow of blood to lymph nodes and its relation to lymphocyte traffic and the immune response | Q36335117 | ||
| Increased lymphangiogenesis in joints of mice with inflammatory arthritis | Q36465469 | ||
| Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines | Q36576750 | ||
| The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development. | Q36723559 | ||
| A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant | Q38098855 | ||
| Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies | Q38753321 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P577 | publication date | 2017-12-07 | |
| P1433 | published in | Pharmaceutics | Q27723332 |
| P1476 | title | Application of Pharmacokinetics Modelling to Predict Human Exposure of a Cationic Liposomal Subunit Antigen Vaccine System | |
| P478 | volume | 9 |
Search more.